TY - JOUR
T1 - Effect of dexmedetomidine on lactate clearance in patients with septic shock
T2 - A subanalysis of a multicenter randomized controlled trial
AU - Miyamoto, Kyohei
AU - Nakashima, Tsuyoshi
AU - Shima, Nozomu
AU - Kato, Seiya
AU - Ueda, Kentaro
AU - Kawazoe, Yu
AU - Ohta, Yoshinori
AU - Morimoto, Takeshi
AU - Yamamura, Hitoshi
N1 - Funding Information:
The original study was supported in part by a noncontractual research grant to Wakayama Medical University provided by Hospira Japan. The present subanalysis was conducted sorely by the academic investigators without any support from pharmaceutical companies. The authors report no conflicts of interest.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Lactate clearance is useful to guide initial resuscitation of patients with septic shock. We conducted this study to evaluate whether dexmedetomidine increases lactate clearance in patients with septic shock. This was a randomized controlled trial that involved a post hoc subgroup analysis. Adult patients with septic shock under ventilation were randomized to receive sedation strategy with or without dexmedetomidine (60 in the dexmedetomidine and 51 in the nondexmedetomidine groups). The primary outcome was the lactate clearance at 6h, defined as the percent decrease in lactate from randomization to 6h after. The median Acute Physiology and Chronic Health Evaluation II score was 25 (interquartile range 19-31). The median serum lactate value at randomization was lower in the dexmedetomidine group than in the nondexmedetomidine group (4.0mmol/L vs. 4.8mmol/L; P=0.053). The lactate clearance at 6h was higher in the dexmedetomidine group, although this was not statistically significant (23.3±29.8 vs. 11.1±54.4, mean difference 12.2, 95% confidence interval (CI), -4.4 to 28.8). After adjusting for the lactate level at randomization, lactate clearance at 6h was significantly higher in the dexmedetomidine group (adjusted mean difference 18.5, 95% CI, 2.2-34.9). There was no statistically significant difference in the 28-day mortality between the dexmedetomidine and the nondexmedetomidine groups (13 [22%] vs. 18 [35%] patients, P=0.11). In conclusion, among mechanically ventilated patients with septic shock, sedation with dexmedetomidine resulted in increased lactate clearance compared with sedation without dexmedetomidine.
AB - Lactate clearance is useful to guide initial resuscitation of patients with septic shock. We conducted this study to evaluate whether dexmedetomidine increases lactate clearance in patients with septic shock. This was a randomized controlled trial that involved a post hoc subgroup analysis. Adult patients with septic shock under ventilation were randomized to receive sedation strategy with or without dexmedetomidine (60 in the dexmedetomidine and 51 in the nondexmedetomidine groups). The primary outcome was the lactate clearance at 6h, defined as the percent decrease in lactate from randomization to 6h after. The median Acute Physiology and Chronic Health Evaluation II score was 25 (interquartile range 19-31). The median serum lactate value at randomization was lower in the dexmedetomidine group than in the nondexmedetomidine group (4.0mmol/L vs. 4.8mmol/L; P=0.053). The lactate clearance at 6h was higher in the dexmedetomidine group, although this was not statistically significant (23.3±29.8 vs. 11.1±54.4, mean difference 12.2, 95% confidence interval (CI), -4.4 to 28.8). After adjusting for the lactate level at randomization, lactate clearance at 6h was significantly higher in the dexmedetomidine group (adjusted mean difference 18.5, 95% CI, 2.2-34.9). There was no statistically significant difference in the 28-day mortality between the dexmedetomidine and the nondexmedetomidine groups (13 [22%] vs. 18 [35%] patients, P=0.11). In conclusion, among mechanically ventilated patients with septic shock, sedation with dexmedetomidine resulted in increased lactate clearance compared with sedation without dexmedetomidine.
KW - Dexmedetomidine
KW - lactate clearance
KW - sedation
KW - septic shock
UR - http://www.scopus.com/inward/record.url?scp=85050161390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050161390&partnerID=8YFLogxK
U2 - 10.1097/SHK.0000000000001055
DO - 10.1097/SHK.0000000000001055
M3 - Article
C2 - 29117063
AN - SCOPUS:85050161390
VL - 50
SP - 162
EP - 166
JO - Shock
JF - Shock
SN - 1073-2322
IS - 2
ER -